Inventiva to participate at the Jefferies Virtual Healthcare Conference
May 25 2021 - 4:00PM
Inventiva to participate at the Jefferies Virtual Healthcare
Conference
Daix (France), May 25,
2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a
clinical-stage biopharmaceutical company focused on the development
of oral small molecule therapies for the treatment of non-alcoholic
steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other
diseases with significant unmet medical need, today announced that
the Company will participate to the upcoming Jefferies Virtual
Healthcare Conference, being held virtually on June 1-4, 2021.
During the event, members of the Company’s leadership will present
a corporate overview, participate in a fireside chat and engage in
1x1 investor meetings.
The event details are as follows:
- Date: Thursday, June 3, 2021
- Time: 9:00 am – 9:25 pm (ET) / 3:00 pm – 3:25
pm (CET)
- Participants: Frédéric Cren, Chairman, CEO and
cofounder of Inventiva, and David Nikodem, Vice President of US
Operations of Inventiva
- Format: Video presentation
- Live and replay link:
https://wsw.com/webcast/jeff174/iva/1694304
The presentation document and the above link
will also be available on Inventiva’s website in the “Investors” –
“Investor Presentations” section. About
Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the development of oral small molecule therapies
for the treatment of NASH, MPS and other diseases with significant
unmet medical need.
Leveraging its expertise and experience in the
domain of compounds targeting nuclear receptors, transcription
factors and epigenetic modulation, Inventiva is currently advancing
two clinical candidates, as well as a deep pipeline of earlier
stage programs.
Lanifibranor, its lead product candidate, is
being developed for the treatment of patients with NASH, a common
and progressive chronic liver disease for which there are currently
no approved therapies. In 2020, Inventiva announced positive
topline data from its Phase IIb clinical trial evaluating
lanifibranor for the treatment of patients with NASH and obtained
Breakthrough Therapy and Fast Track designation for lanifibranor in
the treatment of NASH.
Inventiva is also developing odiparcil, a second
clinical stage asset, for the treatment of patients with subtypes
of MPS, a group of rare genetic disorders. Inventiva announced
positive topline data from its Phase IIa clinical trial evaluating
odiparcil for the treatment of adult MPS VI patients at the end of
2019 and received FDA Fast Track designation in MPS VI for
odiparcil in October 2020.
In parallel, Inventiva is in the process of
selecting an oncology development candidate for its Hippo
signalling pathway program. Furthermore, the Company has
established a strategic collaboration with AbbVie in the area of
autoimmune diseases. AbbVie has started the clinical development of
ABBV‑157, a drug candidate for the treatment of moderate to severe
psoriasis resulting from its collaboration with Inventiva. This
collaboration enables Inventiva to receive milestone payments upon
the achievement of pre-clinical, clinical, regulatory and
commercial milestones, in addition to royalties on any approved
products resulting from the collaboration.
The Company has a scientific team of
approximately 70 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, as well as in clinical development. It also owns
an extensive library of approximately 240,000 pharmacologically
relevant molecules, approximately 60% of which are proprietary, as
well as a wholly‑owned research and development facility.
Inventiva is a public company listed on
compartment C of the regulated market of Euronext Paris (ticker:
IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com
Contacts
InventivaPascaline ClercVP of Global External
Affairsmedia@inventivapharma.com+1 240 620 9175 |
Brunswick GroupYannick Tetzlaff / Tristan Roquet
Montegon / Aude LepreuxMedia
relationsinventiva@brunswickgroup.com+33 1 53 96 83 83 |
Westwicke,
an ICR CompanyPatricia L. BankInvestor
relationspatti.bank@westwicke.com+1 415 513 1284 |
- Inventiva - PR - Jefferies Virtual Healthcare Conference - EN -
25 05 2021
Inventiva (EU:IVA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Inventiva (EU:IVA)
Historical Stock Chart
From Oct 2023 to Oct 2024